General Oncology

A Groundbreaking Treatment For Pancreatic Cancer

About this Event

When Dr. Arnold Glazier, a leading cancer researcher, learned his sister was diagnosed with Pancreatic Cancer, he threw all his efforts into finding a treatment that could extend her life without causing lasting side effects. Since receiving a treatment he designed 13 years ago, she has been pancreatic-cancer free without receiving any maintenance drugs and with no lasting side effects.

This treatment led to the development of GO-4, a clinical-phase drug candidate that recently completed its initial Phase 1 trial for Stage IV Pancreatic Cancer Patients with BRCA mutations. The result, after just two cycles of treatment, yields a median progression-free survival approximately double the standard of care in the intended patient population. General Oncology is presenting these results at ESMO (European Society for Medical Oncology) on October 19th in Berlin, Germany.

GO-4 targets attributes common to all cancer cells without any reported lasting side effects to patients. In addition to Pancreatic cancer, the company is planning to go after Prostate, Breast, and Ovarian Cancer, creating a market worth between $4.5 and $7 billion for GO-4.

In addition, General Oncology has created JG-1, a highly selective, ultra-potent drug candidate that induces terminal proliferation arrest that in an animal study, has shown remarkable promise to treat diabetic retinopathy and wet AMD. Together these diseases have an estimated U.S. market of $14.3B in 2025 that is expected to increase to $33.5B by 2037.

Register to watch our webinar with General Oncology CEO, Jeff Glazier, to learn more about their groundbreaking cure, and the current raise supporting the GO-4 expansion trial, IND filings for JG-1, and readiness to list on NASDAQ.

Video On Demand

– Recorded

November 12

SHARE THIS EVENT

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.